Sherlock Biosciences to gain necessary market foothold in U.S. with newly granted patent

Since their discovery, CRISPR and its related protein (Cas) systems have found an increasing number of uses in the fields of cell imaging, transcriptional regulation, medicines, and diagnostics. The scope of illness diagnosis has expanded with the discovery of Cas12 and Cas13. For the diagnosis of viral infections in humans, animals, and to a lesser extent in plants, these endonucleases have been widely utilised.

The SARS-CoV-2 pandemic's urgency has brought attention to the potential of CRISPR-Cas systems and encouraged the creation of cutting-edge point-of-care diagnostic tools. They are the best prospects for disease diagnosis and management in the future due to the CRISPR chemistry's quick adaptation and its ability to detect new infections with high sensitivity. The difficult task of cancer diagnosis and prognosis has attracted CRISPR-based techniques.

Diagnostics rely on cutting-edge applications of synthetic biology and CRISPR technology to reduce the complexity of typical lab tests and make them portable. Amplification and collateral cleavage are a crucial set of technologies used by Sherlock's CRISPR-based diagnostics to identify disorders and are protected by the patent. In order for the guide RNA to locate and identify a particular nucleic acid signature within a test sample, it must first be amplified. A fluorescently tagged probe contained in the mixture is cleaved by the Cas12 enzyme after the guide RNA finds and binds to the target nucleic acid. This cleavage event sets off a chain of events that eventually lead to the emission of a fluorescent signature, signifying a successful test.

A licencing agreement was reached between Sherlock Biosciences and Shanghai-based Tolo Biotech in November 2022. Sherlock Biosciences engineers biology to deliver next-generation diagnostics to the point-of-need. The agreement gives Cas12 and Cas13 CRISPR diagnostic techniques co-exclusive rights in markets outside of the United States and Greater China.
In 2020, Tolo received the exclusive rights to Sherlock's CRISPR Cas13 SHERLOCK^TM diagnostic platform in Greater China and Tolo's CRISPR Cas12 (including Cas12a and Cas12b) diagnostic technology for use in the United States.
Sherlock Biosciences has recently received a patent from the USPTO for the therapeutic use of the Cas12 enzyme, making it the clear winner in CRISPR-based diagnostics with authorization to operate in the US.
Sherlock maintains exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech in addition to other intellectual property (IP) for Cas12 and Cas13 from the Broad Institute, giving the company the dominant IP position in the sector.

The recently awarded invention relates to a technique for detecting nucleic acids that makes use of Cas12's collateral cleavage activity. Cas12 is better adapted for detecting DNA and RNA sequences than altering them, in contrast to Cas9, the enzyme frequently employed for gene editing and CRISPR-based therapies and the focus of multiple patent battles. Sherlock and its academic co-founders have already shown the promise for adaptable, highly accurate, and inexpensive Cas12-based disease detection, including COVID-19, tuberculosis and malaria.

By giving patients more control, Sherlock's diagnostic procedures have the potential to change the way they receive medical care. Obtaining this patent is a crucial step in bringing effective, over-the-counter diagnostics to market, giving consumers greater say in their healthcare choices.

BioIntel360 suggests that with Cas12 and Cas13 playing a crucial role, it is very clear that the area of CRISPR-Cas-based diagnosis is expected to grow.